Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Assets (2016 - 2025)

Capricor Therapeutics has reported Non-Current Assets over the past 15 years, most recently at $33.0 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $33.0 million for Q4 2025, up 365.2% from a year ago — trailing twelve months through Dec 2025 was $75.5 million (up 152.65% YoY), and the annual figure for FY2025 was $33.0 million, up 365.2%.
  • Non-Current Assets for Q4 2025 was $33.0 million at Capricor Therapeutics, up from $25.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CAPR hit a ceiling of $33.0 million in Q4 2025 and a floor of $928489.0 in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $7.2 million (2022), compared with a mean of $8.4 million.
  • Biggest five-year swings in Non-Current Assets: surged 469.5% in 2022 and later fell 9.94% in 2024.
  • Capricor Therapeutics' Non-Current Assets stood at $4.9 million in 2021, then surged by 47.26% to $7.2 million in 2022, then rose by 9.33% to $7.9 million in 2023, then decreased by 9.94% to $7.1 million in 2024, then soared by 365.2% to $33.0 million in 2025.
  • The last three reported values for Non-Current Assets were $33.0 million (Q4 2025), $25.5 million (Q3 2025), and $9.4 million (Q2 2025) per Business Quant data.